Eucrisa: A Topical Solution for Mild to Moderate Eczema

Abstract

Eucrisa Eczema, also identified as atopic dermatitis, is a significant health problem recognized globally and is a concern to many physicians due to its prevalence. Its evidence in the US population has led to the discovery of Eucrisa (Crisaborole). Eucrisa eczema ointment is a new drug in the market. According to (Pfizer Inc 2016), the US Food and Drug Administration approved Eucrisa bringing relief to patients suffering from Eczema. Eucrisa is a pharmacological agent that is used to treat mild to moderate Eczema in adults. The drug treats children of above three months. According to (Dina 2016), Crisaborole topical ointment, 2% (formerly known as AN2728), is a benzoxaborole, nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor investigational compound that recently completed phase 3 studies for the treatment of minor to moderate atopic dermatitis (AD). Eucrisa is the first and only nonsteroidal topical monotherapy that inhibits the phosphodiesterase (PDE)-4 enzyme in the skin (Pfizer Inc). The drug's compositions are the active agent Crisaborole(20mg), and inactive agents, which include; white petrolatum, propylene glycol, mono- and di-glycerides, paraffin, butylated hydroxytoluene, and edetate calcium disodium. The ability of Crisaborole to inhibit PDE4 enables it to control inflammation. It is also composed of a compound called boron responsible for the skin penetration of the drug. According to (Woo 2019), Crisaborole is an efficacious topical agent with a favorable safety profile and limited systemic exposure and a promising candidate for atopic dermatitis treatment. Eucrisa is for topical use and is not orally, intravaginally, or for ophthalmic use. It is applied in a thin sheet twice daily. Its effectiveness can be as little as eight days but administered as recommended by a doctor. However, Eucrisa can have allergic side effects such as itching, swelling, and redness in the applied area. In case of these effects,...